Globus Medical (GMED) Reaffirms Guidance As Investors Ask If The Stock Is Still A Bargain

Globus Medical (GMED) reaffirmed its full year 2026 revenue guidance and paired that outlook with continued spending on robotics, research projects and manufacturing capacity, a combination that has drawn fresh attention from investors.

The reaffirmed outlook comes at a time when Globus Medical’s share price has fallen 14.5% year to date, while the 1-year total shareholder return is 32%. This combination suggests that recent momentum has cooled even as longer term holders have been rewarded.

Scan Globus Medical’s peers that combine medical technology with substantial R&D spending and robotics by focusing on our hand picked 34 healthcare AI stocks.

So with Globus Medical reaffirming guidance while the share price has cooled this year, does the current set up still tilt the risk reward toward buyers, or has the easy upside already been taken?

Most Popular Narrative: 26% Undervalued

Globus Medical’s most followed narrative pegs fair value at $100.92 against a last close of $74.65. This frames the reaffirmed 2026 guidance against expectations for earnings power and margin execution rather than this year’s share price pullback.

Disciplined capital allocation, including use of roughly half of free cash flow for share repurchases, a debt free balance sheet with US$840.5 million of cash and securities, and early delivery of NuVasive and Nevro synergy and EPS accretion targets, supports the potential for higher EPS and cash flow per share.

See why 21 investors see Globus Medical as 26% undervalued.

Result: Fair Value of $100.92 (UNDERVALUED)

Still, if Enabling Technologies and Nevro continue to report weak or volatile revenue, or if hospital capital budgets tighten further, the bullish Globus Medical margin story could stall.

Find out about the key risks to this Globus Medical narrative.

Next Steps

If the upbeat tone of the Globus Medical narrative still feels debatable, you may wish to act while sentiment is mixed and review the story yourself. Start by weighing the 5 key rewards.

Looking for more Globus Medical style investment ideas?

Do not stop with Globus Medical. Broaden your watchlist with a few focused stock pools that match different goals so you do not miss the next opportunity.

• Target resilient compounding potential by scanning a 31 resilient stocks with low risk scores that aims to keep drawdowns in check while still giving room for upside.
• Hunt for quality at a sensible price through a 28 high quality undervalued stocks that filters for solid businesses trading below their estimated worth.
• Prioritise strength and staying power by reviewing a list of solid balance sheet and fundamentals (25 results) that focuses on firms with robust finances backing their operations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com